tiprankstipranks
Rhythm Pharmaceuticals (RYTM)
NASDAQ:RYTM
US Market
RYTM
Rhythm Pharmaceuticals
RESEARCH TOOLSreports
Want to see RYTM full AI Analyst Report?

Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

613 Followers
See the Price Targets and Ratings of:

RYTM Analyst Ratings

Strong Buy
12Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Rhythm
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RYTM Stock 12 Month Forecast

Average Price Target

$137.75
▲(55.32% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Rhythm Pharmaceuticals in the last 3 months. The average price target is $137.75 with a high forecast of $159.00 and a low forecast of $105.00. The average price target represents a 55.32% change from the last price of $88.69.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"62":"$62","111":"$111","160":"$160","86.5":"$86.5","135.5":"$135.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":159,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$159.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":137.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$137.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$105.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[62,86.5,111,135.5,160],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.87,93.34153846153846,98.81307692307692,104.28461538461539,109.75615384615385,115.22769230769231,120.69923076923078,126.17076923076924,131.6423076923077,137.11384615384617,142.5853846153846,148.05692307692308,153.52846153846156,{"y":159,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.87,91.70692307692308,95.54384615384616,99.38076923076923,103.21769230769232,107.05461538461539,110.89153846153846,114.72846153846154,118.56538461538462,122.40230769230769,126.23923076923077,130.07615384615383,133.91307692307691,{"y":137.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.87,89.18769230769232,90.50538461538461,91.82307692307693,93.14076923076924,94.45846153846153,95.77615384615385,97.09384615384616,98.41153846153847,99.72923076923077,101.04692307692308,102.36461538461538,103.68230769230769,{"y":105,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":63.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.21,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.76,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.04,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.04,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.99,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.94,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.12,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.81,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.87,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$159.00Average Price Target$137.75Lowest Price Target$105.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on RYTM
Derek Archila
Wells Fargo
Wells Fargo
$175→$155
Buy
74.77%
Upside
Assigned
06/17/26
Rhythm Pharmaceuticals price target raised to $155 from $144 at Wells FargoRhythm Pharmaceuticals price target raised to $155 from $144 at Wells Fargo
TD Cowen Analyst forecast on RYTM
Phil Nadeau
TD Cowen
TD Cowen
$130
Buy
46.58%
Upside
Reiterated
06/17/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Canaccord Genuity Analyst forecast on RYTM
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$143→$151
Buy
70.26%
Upside
Reiterated
06/16/26
Rhythm Pharmaceuticals: Buy Rating Reaffirmed as Strong PWS Data Lift 2033 Outlook and Price Target Raised to $151 from $143
Guggenheim Analyst forecast on RYTM
Seamus Fernandez
Guggenheim
Guggenheim
$143
Buy
61.24%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Rhythm Pharmaceuticals (NASDAQ: RYTM) and Damora Therapeutics (NASDAQ: DMRA)
H.C. Wainwright Analyst forecast on RYTM
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$105
Buy
18.39%
Upside
Reiterated
06/15/26
Rhythm Pharmaceuticals: Buy Rating Reiterated on Promising PWS Data and Large Market Opportunity; $105 Price Target Unchanged
Needham Analyst forecast on RYTM
Joseph Stringer
Needham
Needham
$130
Buy
46.58%
Upside
Reiterated
06/15/26
Rhythm Pharmaceuticals: Phase 2 PWS Data Strengthen Outlook as Buy Rating and $130 Price Target Are Reaffirmed
Stifel Nicolaus Analyst forecast on RYTM
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$133
Buy
49.96%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA), Rhythm Pharmaceuticals (NASDAQ: RYTM) and Belite Bio, Inc. ADR (NASDAQ: BLTE)
Bank of America Securities Analyst forecast on RYTM
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$149
Buy
68.00%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), Ionis Pharmaceuticals (NASDAQ: IONS) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Jefferies Analyst forecast on RYTM
Dennis Ding
Jefferies
Jefferies
$125
Buy
40.94%
Upside
Reiterated
06/15/26
Rhythm Pharmaceuticals (RYTM) Receives a Buy from Jefferies
Goldman Sachs Analyst forecast on RYTM
Corinne Johnson
Goldman Sachs
Goldman Sachs
$158→$159
Buy
79.28%
Upside
Reiterated
06/14/26
Rhythm Pharmaceuticals (RYTM) Receives a Buy from Goldman Sachs
Morgan Stanley Analyst forecast on RYTM
Michael Ulz
Morgan Stanley
Morgan Stanley
$136
Buy
53.34%
Upside
Reiterated
06/14/26
Buy Rating Reaffirmed on Rhythm as PWS Data Strengthens Thesis; $136 Price Target Maintained
RBC Capital Analyst forecast on RYTM
Lisa Walter
RBC Capital
RBC Capital
$136→$137
Buy
54.47%
Upside
Reiterated
05/05/26
Analysts' Top Healthcare Picks: Xencor (XNCR), Rhythm Pharmaceuticals (RYTM)
Citi Analyst forecast on RYTM
Samantha Semenkow
Citi
Citi
$131→$142
Buy
60.11%
Upside
Assigned
03/20/26
Rhythm Pharmaceuticals price target lowered to $131 from $136 at CitiRhythm Pharmaceuticals price target lowered to $131 from $136 at Citi
Citizens JMP Analyst forecast on RYTM
Jonathan Wolleben
Citizens JMP
Citizens JMP
$176→$152
Buy
71.38%
Upside
Reiterated
03/17/26
Rhythm Pharmaceuticals price target lowered to $152 from $176 at CitizensRhythm Pharmaceuticals price target lowered to $152 from $176 at Citizens
Oppenheimer Analyst forecast on RYTM
Leland Gershell
Oppenheimer
Oppenheimer
―
Hold
―
Downgraded
11/04/25
Oppenheimer downgrades Rhythm Pharmaceuticals (RYTM) to a Hold
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on RYTM
Derek Archila
Wells Fargo
Wells Fargo
$175→$155
Buy
74.77%
Upside
Assigned
06/17/26
Rhythm Pharmaceuticals price target raised to $155 from $144 at Wells FargoRhythm Pharmaceuticals price target raised to $155 from $144 at Wells Fargo
TD Cowen Analyst forecast on RYTM
Phil Nadeau
TD Cowen
TD Cowen
$130
Buy
46.58%
Upside
Reiterated
06/17/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Canaccord Genuity Analyst forecast on RYTM
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$143→$151
Buy
70.26%
Upside
Reiterated
06/16/26
Rhythm Pharmaceuticals: Buy Rating Reaffirmed as Strong PWS Data Lift 2033 Outlook and Price Target Raised to $151 from $143
Guggenheim Analyst forecast on RYTM
Seamus Fernandez
Guggenheim
Guggenheim
$143
Buy
61.24%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Rhythm Pharmaceuticals (NASDAQ: RYTM) and Damora Therapeutics (NASDAQ: DMRA)
H.C. Wainwright Analyst forecast on RYTM
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$105
Buy
18.39%
Upside
Reiterated
06/15/26
Rhythm Pharmaceuticals: Buy Rating Reiterated on Promising PWS Data and Large Market Opportunity; $105 Price Target Unchanged
Needham Analyst forecast on RYTM
Joseph Stringer
Needham
Needham
$130
Buy
46.58%
Upside
Reiterated
06/15/26
Rhythm Pharmaceuticals: Phase 2 PWS Data Strengthen Outlook as Buy Rating and $130 Price Target Are Reaffirmed
Stifel Nicolaus Analyst forecast on RYTM
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$133
Buy
49.96%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA), Rhythm Pharmaceuticals (NASDAQ: RYTM) and Belite Bio, Inc. ADR (NASDAQ: BLTE)
Bank of America Securities Analyst forecast on RYTM
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$149
Buy
68.00%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), Ionis Pharmaceuticals (NASDAQ: IONS) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Jefferies Analyst forecast on RYTM
Dennis Ding
Jefferies
Jefferies
$125
Buy
40.94%
Upside
Reiterated
06/15/26
Rhythm Pharmaceuticals (RYTM) Receives a Buy from Jefferies
Goldman Sachs Analyst forecast on RYTM
Corinne Johnson
Goldman Sachs
Goldman Sachs
$158→$159
Buy
79.28%
Upside
Reiterated
06/14/26
Rhythm Pharmaceuticals (RYTM) Receives a Buy from Goldman Sachs
Morgan Stanley Analyst forecast on RYTM
Michael Ulz
Morgan Stanley
Morgan Stanley
$136
Buy
53.34%
Upside
Reiterated
06/14/26
Buy Rating Reaffirmed on Rhythm as PWS Data Strengthens Thesis; $136 Price Target Maintained
RBC Capital Analyst forecast on RYTM
Lisa Walter
RBC Capital
RBC Capital
$136→$137
Buy
54.47%
Upside
Reiterated
05/05/26
Analysts' Top Healthcare Picks: Xencor (XNCR), Rhythm Pharmaceuticals (RYTM)
Citi Analyst forecast on RYTM
Samantha Semenkow
Citi
Citi
$131→$142
Buy
60.11%
Upside
Assigned
03/20/26
Rhythm Pharmaceuticals price target lowered to $131 from $136 at CitiRhythm Pharmaceuticals price target lowered to $131 from $136 at Citi
Citizens JMP Analyst forecast on RYTM
Jonathan Wolleben
Citizens JMP
Citizens JMP
$176→$152
Buy
71.38%
Upside
Reiterated
03/17/26
Rhythm Pharmaceuticals price target lowered to $152 from $176 at CitizensRhythm Pharmaceuticals price target lowered to $152 from $176 at Citizens
Oppenheimer Analyst forecast on RYTM
Leland Gershell
Oppenheimer
Oppenheimer
―
Hold
―
Downgraded
11/04/25
Oppenheimer downgrades Rhythm Pharmaceuticals (RYTM) to a Hold
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Rhythm Pharmaceuticals

3 Months
Whitney IjemCanaccord Genuity
Success Rate
18/23 ratings generated profit
78%
Average Return
+16.77%
Copying Whitney Ijem's trades and holding each position for 3 Months would result in 78.26% of your transactions generating a profit, with an average return of +16.77% per trade.
1 Year
Whitney IjemCanaccord Genuity
Success Rate
22/23 ratings generated profit
96%
Average Return
+62.63%
Copying Whitney Ijem's trades and holding each position for 1 Year would result in 95.65% of your transactions generating a profit, with an average return of +62.63% per trade.
2 Years
Whitney IjemCanaccord Genuity
Success Rate
22/23 ratings generated profit
96%
Average Return
+109.84%
Copying Whitney Ijem's trades and holding each position for 2 Years would result in 95.65% of your transactions generating a profit, with an average return of +109.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RYTM Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
1
15
17
18
10
Buy
28
25
19
24
19
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
29
40
36
42
29
In the current month, RYTM has received 29 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RYTM average Analyst price target in the past 3 months is 137.75.
Each month's total comprises the sum of three months' worth of ratings.

RYTM Financial Forecast

RYTM Earnings Forecast

Next quarter’s earnings estimate for RYTM is -$0.81 with a range of -$1.03 to -$0.60. The previous quarter’s EPS was -$0.83. RYTM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RYTM has Performed in-line its overall industry.
Next quarter’s earnings estimate for RYTM is -$0.81 with a range of -$1.03 to -$0.60. The previous quarter’s EPS was -$0.83. RYTM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RYTM has Performed in-line its overall industry.

RYTM Sales Forecast

Next quarter’s sales forecast for RYTM is $67.53M with a range of $64.00M to $70.88M. The previous quarter’s sales results were $60.11M. RYTM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RYTM has Performed in-line its overall industry.
Next quarter’s sales forecast for RYTM is $67.53M with a range of $64.00M to $70.88M. The previous quarter’s sales results were $60.11M. RYTM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RYTM has Performed in-line its overall industry.

RYTM Stock Forecast FAQ

What is RYTM’s average 12-month price target, according to analysts?
Based on analyst ratings, Rhythm Pharmaceuticals’s 12-month average price target is 137.75.
    What is RYTM’s upside potential, based on the analysts’ average price target?
    Rhythm Pharmaceuticals has 55.32% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RYTM a Buy, Sell or Hold?
          Rhythm Pharmaceuticals has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Rhythm Pharmaceuticals’s price target?
            The average price target for Rhythm Pharmaceuticals is 137.75. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $159.00 ,the lowest forecast is $105.00. The average price target represents 55.32% Increase from the current price of $88.69.
              What do analysts say about Rhythm Pharmaceuticals?
              Rhythm Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of RYTM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.